SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-099251
Filing Date
2024-04-17
Accepted
2024-04-17 17:19:33
Documents
17
Period of Report
2024-04-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d795618d8k.htm   iXBRL 8-K 49992
2 EX-3.1 d795618dex31.htm EX-3.1 29054
3 EX-4.1 d795618dex41.htm EX-4.1 363140
4 EX-99.1 d795618dex991.htm EX-99.1 9460
5 EX-99.2 d795618dex992.htm EX-99.2 5957
  Complete submission text file 0001193125-24-099251.txt   691799

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA vnda-20240417.xsd EX-101.SCH 2889
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20240417_lab.xml EX-101.LAB 18739
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20240417_pre.xml EX-101.PRE 11733
20 EXTRACTED XBRL INSTANCE DOCUMENT d795618d8k_htm.xml XML 3859
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 24851999
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)